|
Malignant neoplasm of prostate
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
The median follow-up was 66.6 mo.Patients with CDK12 mutant prostate cancer exhibited shorter time to metastasis (median = 34.9 mo, p = 0.004) and development of castration-resistant disease (median = 32.7 mo, p < 0.001), compared with other genomic subtypes, with shorter time to PSA progression on first-line ARPI treatment of metastatic castration-resistant disease (median = 3.6 mo, p = 0.0219).
|
31640893 |
2020 |
|
Malignant neoplasm of prostate
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
|
29906450 |
2018 |
|
Malignant neoplasm of prostate
|
0.330 |
Biomarker
|
disease |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Ovarian Carcinoma
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
CDK12 is a recurrently mutated gene in serous ovarian carcinoma, whose downregulation is associated with impaired expression of DNA damage repair genes and subsequent hypersensitivity to DNA-damaging agents and PARP1/2 inhibitors.
|
26787835 |
2016 |
|
Ovarian Carcinoma
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
CDK12 mutations have been reported in many cancers and have been suggested as a cause of defective DNA repair in ovarian carcinoma.
|
27662623 |
2016 |
|
Malignant neoplasm of prostate
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Moreover, CDK12-inactivating mutations together with the TD-plus phenotype were also observed in prostate cancers.
|
26787835 |
2016 |
|
Malignant neoplasm of ovary
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
This genomic instability, denoted as the CDK12 TD-plus phenotype, is remarkably distinct from other alteration patterns described in breast and ovarian cancers.
|
26787835 |
2016 |
|
Malignant neoplasm of ovary
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
CDK12 mutations have been reported in many cancers and have been suggested as a cause of defective DNA repair in ovarian carcinoma.
|
27662623 |
2016 |
|
Ovarian Carcinoma
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
CDK12 is among only nine genes with recurrent somatic mutations in high-grade serous ovarian carcinoma.
|
25712099 |
2015 |
|
Malignant neoplasm of ovary
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
CDK12 is among only nine genes with recurrent somatic mutations in high-grade serous ovarian carcinoma.
|
25712099 |
2015 |
|
Ovarian Carcinoma
|
0.330 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Malignant neoplasm of ovary
|
0.330 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Neoplasm of uncertain or unknown behavior of ovary
|
0.300 |
CausalMutation
|
disease |
CGI |
|
|
|
|
ovarian neoplasm
|
0.300 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Adenocarcinoma of large intestine
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDK12 is a promising therapeutic target in breast cancer with effective cancer cell stemness maintainess ability.
|
31744448 |
2020 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this report, we evaluate the clinical characteristics and outcomes of patients with prostate cancer and CDK12 mutation in their tumors.
|
31640893 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
CDK12 is a promising therapeutic target in breast cancer with effective cancer cell stemness maintainess ability.
|
31744448 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we demonstrate that CDK12 promotes tumor initiation as a novel regulator of cancer stem cells (CSCs) and induces anti-HER2 therapy resistance in human breast cancer.
|
31468695 |
2019 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CDK12 is a kinase associated with elongating RNA polymerase II (RNAPII) and is frequently mutated in cancer.
|
31347271 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation.
|
30988284 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Detection of <i>CDK12-</i>LOF genomic alterations and their association with FTDs in a diverse spectrum of malignancies suggests that immunotherapy approaches targeting FINAs derived from <i>CDK12-</i>associated FTDs may be a broadly applicable strategy that could be explored across cancer types in a tumor-agnostic manner.
|
31292271 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The RNA polymerase II (RNAPII) C-terminal domain kinase, CDK12, regulates genome stability, expression of DNA repair genes, and cancer cell resistance to chemotherapy and immunotherapy.
|
30819820 |
2019 |
|
Glomerular Filtration Rate
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Trans-ethnic kidney function association study reveals putative causal genes and effects on kidney-specific disease aetiologies.
|
30604766 |
2019 |